Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-222843
Filing Date
2026-05-14
Accepted
2026-05-14 07:56:16
Documents
65
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q pyxs-20260331.htm   iXBRL 10-Q 1972682
2 EX-10.1 pyxs-ex10_1.htm EX-10.1 187223
3 EX-31.1 pyxs-ex31_1.htm EX-31.1 16820
4 EX-31.2 pyxs-ex31_2.htm EX-31.2 16610
5 EX-32.1 pyxs-ex32_1.htm EX-32.1 10393
6 EX-32.2 pyxs-ex32_2.htm EX-32.2 9461
7 GRAPHIC img17314943_0.jpg GRAPHIC 696601
  Complete submission text file 0001193125-26-222843.txt   9722271

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pyxs-20260331.xsd EX-101.SCH 1295480
69 EXTRACTED XBRL INSTANCE DOCUMENT pyxs-20260331_htm.xml XML 1135707
Mailing Address 321 HARRISON AVENUE BOSTON MA 02118
Business Address 321 HARRISON AVENUE BOSTON MA 02118 (617) 221-9059
Pyxis Oncology, Inc. (Filer) CIK: 0001782223 (see all company filings)

EIN.: 831160910 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40881 | Film No.: 26975903
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)